Abstract
A nine-year-old girl presented with headache, purpura and mild left hemiparesis. Laboratory evaluation revealed thrombotic microangiopathy with ADAMTS13 deficiency, with auto-antibodies to ADAMTS13. She was treated with plasma exchange and steroids, following which she improved transiently, relapsing within 2 months. The relapse was refractory to conventional therapy and rituximab was tried. She had good response to rituximab and has been in remission for the past 12 months. Rituximab may be a promising option for children with acquired TTP refractory to plasma exchange and steroids.
This is a preview of subscription content, log in via an institution to check access.
References
Kremer Hovinga JA, Mottini M, Lammle B. Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost. 2006;4:1146–8.
Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, Mackie I, Machin SJ. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136:451–61.
Franchini M. Thrombotic microangiopathies: an update. Hematology. 2006;11:139–46.
Loirat C, Veyradier A, Girma J-P, Ribba A-S, Meyer D. Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children. Semin Thromb Hemost. 2006;32:90–7.
Bouw MC, Dors N, van Ommen H, Ramakers-van Woerden NL. Thrombotic thrombocytopenic purpura in childhood. Pediatr Blood Cancer. 2009;53:537–42.
Piastra M, Currò V, Chiaretti A, Viola L, Tortorolo L, Polidori G. Intracranial hemorrhage at the onset of thrombotic thrombocytopenic purpura in an infant: therapeutic approach and intensive care management. Pediatr Emerg Care. 2001;17:42–5.
Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology. 2004;2004:407–23.
Caramazza D, Quintini G, Abbene I, Coco LL, Malato A, Di Trapani R, et al. Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura—haemolytic uraemic syndrome. Blood Transfus. 2010;8:203–10.
Fakhouri F, Vernant J-P, Veyradier A, Wolf M, Kaplanski G, Binaut R, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood. 2005;106:1932–7.
Albaramki JH, Teo J, Alexander SI. Rituximab therapy in two children with autoimmune thrombotic thrombocytopenic purpura. Pediatr Nephrol. 2009;24:1749–52.
Jayabose S, Dunbar J, Nowicki TS, Tugal O, Ozkaynak MF, Sandoval C. Rituximab therapy to prevent relapse in chronic relapsing thrombotic thrombocytopenic purpura (TTP) in a child. Pediatr Hematol Oncol. 2011;28:167–72.
Arici B, Trendelenburg M. Successful treatment of thrombotic thrombocytopenic purpura (TTP) with rituximab. Ther Umsch. 2008;65:710–2.
Curtillet C, Poullin P, Doré E, Fossat C, Lefevre P, Michel G. Paediatric case report of an acquired autoimmune thrombotic thrombocytopenic purpura. Arch Pediatr. 2006;13:1521–4.
Harambat J, Lamireau D, Delmas Y, Ryman A, Llanas B, Brissaud O. Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: a pediatric report and literature review. Pediatr Crit Care Med. 2011;12:e90–3.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Narayanan, P., Jayaraman, A., Rustagi, R.S. et al. Rituximab in a child with autoimmune thrombotic thrombocytopenic purpura refractory to plasma exchange. Int J Hematol 96, 122–124 (2012). https://doi.org/10.1007/s12185-012-1089-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-012-1089-7